Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
EMR Versus CSP in the Treatment of Sessile Serrated Lesions Less Than 10mm in Size
Not Applicable
Not yet recruiting
- Conditions
- Colorectal Sessile Serrated Lesion
- Interventions
- Procedure: endoscopic mucosal resectionProcedure: Cold snare polypectomy
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 270
- Registration Number
- NCT06609031
- Locations
- 🇨🇳
Huadong hospital affiliated to Fudan university, Shanghai, China
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastasases
- Interventions
- Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 800
- Registration Number
- NCT06604689
- Locations
- 🇨🇳
Shanghai Cancer center, Shanghai, Shanghai, China
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Vitmain C plus herbal medicine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06601283
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06598033
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06593548
- Locations
- 🇨🇳
Xinxiang Li, Shanghai, Shanghai, China
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
Recruiting
- Conditions
- Breast Neoplasms
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20000
- Registration Number
- NCT06591039
- Locations
- 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
Phase 2
Not yet recruiting
- Conditions
- Gallbladder Cancer Unresectable
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 33
- Registration Number
- NCT06591650
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors
Not Applicable
Active, not recruiting
- Conditions
- Primary Liver CancerColorectal Cancer Liver Metastases
- Interventions
- Device: Multi-mode tumor treatment systemDevice: Radiofrequency ablation therapeutic apparatus
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06588569
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
Phase 1
Not yet recruiting
- Conditions
- NMIBC
- Interventions
- Drug: SHR-1501+SHR-2005
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 58
- Registration Number
- NCT06588179
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Phase 2
Recruiting
- Conditions
- Lymphoma, B-Cell, Marginal Zone
- Interventions
- Radiation: response-adapted radiation
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06583837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath